Introduction {#sec1-1}
============

Rheumatoid factor (RF) is an autoantibody directed against the Fc portion of immunoglobulin G and is found in every 3 of 4 patients with rheumatoid arthritis (RA) ([@ref1], [@ref2]). Being not specific for RA, RF is found in other diseases, including Sjogren's syndrome, systemic lupus erythematosus, hepatitis C, and subacute bacterial endocarditis, as well as in 5% of healthy persons, at an increasing prevalence with age ([@ref1], [@ref2]). Seropositivity in RA can be of prognostic significance inasmuch as patients with elevated titers tend to have more severe and progressive disease with extra-articular manifestations, including vasculitis, thus helping guide the physicians to more aggressive treatment ([@ref1]-[@ref3]).

Lipoprotein (Lp)(a) is a cardiovascular risk factor and is known to promote thrombosis, inflammation, and coronary artery disease ([@ref4], [@ref5]). Two findings-namely, the independent and inverse association with fasting triglyceride in subjects with MetS ([@ref6]) and in women with serum γ-glutamyltransferase ([@ref6]) led us to hypothesize that an inverse association of Lp(a) may appear in pro-inflammatory state/oxidative stress, whereby low Lp(a) levels might actually represent failure of the assayability of Lp(a) in an immune complex and result from pro-inflammatory state/oxidative stress ([@ref7]). As an LDL-like particle consisting of an apoB100 molecule linked to a glycoprotein, apolipoprotein (a), Lp(a) has been recognized to be in a very weak correlation with other lipid and non-lipid parameters ([@ref4], [@ref8], [@ref9]). This particle's function remains largely uncertain; Lp(a) binds proinflammatory-oxidized phospholipids ([@ref10]) and is a preferential carrier of oxidized phospholipids (ox-PL) in human plasma. Lp(a) also contains lipoprotein-associated phospholipase A~2~ (Lp-PLA~2~ (or PAF-AH)), which may cleave oxidized fatty acids to yield short-chain fatty acids and lysolecithin ([@ref11]).

To our knowledge, the association between the presence of RF and Lp(a) has at best scarcely been studied, as has been RF's association with metabolic disorders, such as diabetes or hypertension. We, therefore, investigated these relationships of RF in a representative sample of middle-aged Turkish adults, with an emphasis on the relationship with markers of diabetes risk. Current findings shed light on the link of Lp(a) to RF and provide evidence for the interplay of the immune mechanism, as well as for a novel potential immune pathway in the development of type 2 diabetes that may be shared with RA ([@ref12]).

Methods {#sec1-2}
=======

The study sample of the longitudinal TARF study ([@ref13], [@ref14]), a representative sample of Turkey's middle-aged and elderly adults, is formed by all participants who attended the survey in 2011/2012 (n=1551). They were aged 40 years or over and resided in all regions of Turkey. Eight men and 4 women who had substantial renal functional impairment, as assessed by serum creatinine \>227 μmol/L, were excluded. The study was approved by the Ethics Committee of the İstanbul University İstanbul Medical Faculty. Written informed consent was obtained from all participants.

Measurements of risk variables {#sec2-1}
------------------------------

Waist circumference was measured with the subject standing at the end of gentle expiration at the level midway between the lower rib margin and the iliac crest. Status of cigarette smoking was categorized into current, former, and never-smokers. Blood pressure (BP) was measured in the seated position on the right arm using an aneroid sphygmomanometer (Erka, Bad Tölz, Germany) after 5 minutes of rest, and the mean of two recordings was computed.

Serum concentrations of total cholesterol, fasting triglycerides, glucose, and high-density lipoprotein (HDL)-cholesterol (directly without precipitation) were determined using enzymatic kits from Roche Diagnostics. Concentrations of insulin, sex hormone-binding globulin (SHBG), and total testosterone were determined by the electrochemiluminescent immunoassay method using Roche kits and an Elecsys 1010 immunoautoanalyzer (Roche Diagnostics, Mannheim, Germany). Concentrations of serum Lp(a), apoA-I apoB, C-reactive protein (CRP), RF, and complement C3c were measured by Behring kits and Behring nephelometry (Behring Diagnostics, Marburg, Germany, or Westwood, MA). Fasting sera were assayed for concentrations of acylation-stimulating protein (ASP) with ELISA kits purchased from Biotechist Co. (Beijing, China).

Definitions {#sec2-2}
-----------

Individuals with diabetes were diagnosed with criteria of the American Diabetes Association ([@ref15]), namely, when plasma fasting glucose was ≥7 mmol/L (or 2-h postprandial glucose ≥11.1 mmol/L) and/or the current use of diabetes medication. Individuals having a fasting glucose level of 5.6-6.9 mmol/L were designated as prediabetes ([@ref16]). Hypertension was defined as blood pressure ≥140 mm Hg and/or \>90 mm Hg and/or use of antihypertensive medication.

Statistical analysis {#sec2-3}
--------------------

Descriptive parameters were shown as means \[± standard deviation (SD)\]. Due to skewed distribution, geometric means were used uniformly for triglycerides, CRP insulin, SHBG, testosterone, ASP and Lp(a) values. RF assays did not detect titers \<10 lU/mL, which were therefore considered negative. To analyze the differences between continuous variables with normal distribution, student's t-test and between-categorical variables Pearson's chi-square test were used. Pearson's correlations served to analyze univariate correlations. Sex- and age-adjusted associations for RF positivity were assessed in multiple logistic regression analyses for diabetes and hypertension, whereby likelihood estimates (OR) and 95% confidence intervals (CIs) were obtained. A value of p\<0.05 on the two-tailed test was considered statistically significant. Statistical analyses were performed using SPSS-10 for Windows (Chicago, IL, USA).

Results {#sec1-3}
=======

The study sample consisted of 1539 men and women (n=792) at a mean age of 58.8 ±10.6 years. RF positivity was found in 75 subjects (5%, 42 men). Values considered to be positive ranged from 10.6 to 200 (median 39) IU/mL.

Subjects reacting positively for RF were 5 years older, had fewer current smokers (p=0.03), had lower fasting triglycerides by 13% (p=0.025), had higher fibrinogen (by 10%, p=0.027) and SHBG (by 11%, 44.3 vs. 40.1 nmol/L, p\<0.12) concentrations, and more frequently had type 2 diabetes (32.4% vs. 20.3%, p=0.017) and hypertension (64% vs. 50.5%, p=0.022). Clinical characteristics, stratified by gender and RF status, are presented in [Table 1](#T1){ref-type="table"}. Men reacting positively for RF had, in addition, significantly (2.0-fold) higher Lp(a) and higher systolic and diastolic BP (by 9/4.5 mm Hg). Women positive for RF showed no further significant differences compared to those negative for RF. RF-positive (compared with RF-negative) women tended to have lower creatinine and a slightly more favorable lipid and metabolic profile.

###### 

Anthropometric and biochemical mean values of the study sample by gender and RF status

                                                                                                    Men n=747   Women n=792                                                          
  ---------------------------------------------------------- -------------------------------------- ----------- ------------- ------- ------ --------- ------- ------ ------- ------ -------
  Sex, n, %                                                  1539                                   713                       42      5.9              763            33      4.1    0.19
  Age, years                                                 1539                                   58.4        10.5          64.7    11.9   \<0.001   58.9    10.8   63.8    10.7   0.014
  Height, cm                                                 1539                                   169.4       6.9           168.5   5.8    0.41      156.2   7.1    155.8   6.2    0.77
  Waist circum., cm                                          1539                                   98.3        11            97      11     0.45      97.8    12.8   97.3    14.2   0.84
  Systolic BP, mm Hg                                         1539                                   121         17.4          130.4   25     0.02      125.8   20     128.3   17     0.49
  Diastolic BP, mm Hg                                        1539                                   75.2        10            79.7    13     0.006     77      11.7   78      9      0.63
  ASP,^[¶](#t1f1){ref-type="table-fn"}^ nmol/L               782                                    8.30        2.41          11.0    2.53   0.37      9.21    2.5    11.3    2.02   0.34
  Total cholest, mmol/L                                      1539                                   5.04        1.05          5.02    1.04   0.91      5.39    1.03   5.24    1.12   0.40
  LDL cholest, mmol/L                                        1539                                   3.09        0.9           3.14    0.89   0.74      3.32    0.89   3.17    0.99   0.14
  HDL cholest, mmol/L                                        1539                                   1.08        0.39          1.12    0.30   0.40      1.30    0.34   1.38    0.25   0.33
  F. triglyceride,^[¶](#t1f1){ref-type="table-fn"}^ mmol/L   1539                                   1.59        1.69          1.42    1.68   0.23      1.58    1.58   1.39    1.57   0.21
  Fast glucose, mmol/L                                       1535                                   5.70        2.3           5.84    1.8    0.79      5.68    2.36   5.49    1.98   0.71
  Fast insulin,^[¶](#t1f1){ref-type="table-fn"}^ mIU/L       1407                                   8.72        2.08          8.50    1.95   0.81      9.02    1.91   7.54    1.86   0.14
  Apolipoprotein A-I, g/L                                    1478                                   1.356       0.23          1.385   0.14   0.41      1.51    0.25   1.523   0.20   0.76
  Apolipoprotein B, g/L                                      1483                                   1.03        0.26          1.10    0.27   0.12      1.05    0.27   1.06    0.30   0.79
  Lipoprot.(a),^[¶](#t1f1){ref-type="table-fn"}^ mg/dl       1305                                   10.4        2.86          20.9    2.72   \<0.001   13.3    2.9    12.35   2.6    0.72
  Creatinine, μmol/L                                         1539                                   106         19            110     21.5   0.24      88      19     86      17     0.47
  Fibrinogen, μmol/L                                         1251                                   103.7       32            117.3   40     0.07      115.6   33.7   126     31.6   0.18
  C-react. prot.,^[¶](#t1f1){ref-type="table-fn"}^ mg/L      1539                                   1.90        2.59          2.19    3.04   0.35      2.45    2.87   2.78    2.43   0.49
  Complement C3, g/L                                         698                                    1.28        0.27          1.33    0.30   0.50      1.33    0.28   1.37    0.37   0.49
  SHBG^[¶](#t1f1){ref-type="table-fn"}^ nmol/L               1304                                   35.1        1.57          40      1.76   0.103     44.8    1.76   50.4    1.52   0.27
  Total testo.,^[¶](#t1f1){ref-type="table-fn"}^ nmol/L      1322                                   12.1        2.25          12.6    2.46   0.77      0.62    2.49   0.66    2.44   0.71
  Curr. & past smok., n                                      1538                                   243         287           8       23     0.088     109     79     2       4      0.40
  Prediabetes, n                                             1245[\*](#t1f2){ref-type="table-fn"}   60          8.4           4       9.5    0.56      77      12.3   3       12.5   0.98
  Diabetes, n                                                1395[\*](#t1f2){ref-type="table-fn"}   133         20.4          13      34.2   0.042     139     20.3   9       30\.   0.20

log-transformed values; ASP - acylation-stimulating protein

total number excludes the other dysglycemic category

Correlation between SHBG and Lp(a) according to RF status {#sec2-4}
---------------------------------------------------------

In 4/5 of the sample, simultaneous Lp(a) and SHBG measures were available. In 1161 RF-negative subjects, Lp(a) was positively though weakly correlated with SHBG in each sex and combined genders (r=0.08; p=0.007) ([Fig. 1](#F1){ref-type="fig"}). Among 61 RF-positive individuals, SHBG was inversely correlated with Lp(a) in each sex and combined genders (r=-0.32, p=0.011). Lp(a) concentrations were positively correlated with RF titers (r=0.32 in men, 0.17 in women).

![Graph depicting the correlation between log-transformed serum lipoprotein (Lp)(a) (in mg/dL) and sex hormone-binding globulin (SHBG, in nmol/L) in 1116 RF-negative and 61 RF-positive participants. The respective regression lines cross each other at about 40 nmol/L of SHBG, above which the RF-positive group is distinct from the large RF-negative group by displaying disproportionately frequent Lp(a) values \<20 mg/dL. The distinction manifests in a positive correlation coefficient (0.08) of sero-negative individuals, shifting to a negative one (-0.32) in sero-positive subjects](AJC-15-782-g001){#F1}

[Table 2](#T2){ref-type="table"} shows two logistic regression analyses for RF positivity. The first model comprised sex, age, Lp(a), CRP, SHBG, and statin usage, all recognized biomarkers and variables associated with metabolic disorders. The model disclosed age and Lp(a) (OR 1.22, 95% CI 1.03; 1.45) to be significantly positively and independently associated in men. Age alone was associated in this model in women, wherein Lp(a) had an OR below unity. In the second model with fasting glucose categories, diabetes attained only borderline significance in the total sample \[OR 1.63 (95% CI 0.96; 2.77)\]. Individuals with prediabetes were not associated with RF positivity.

###### 

Logistic regression analysis for rheumatoid factor positivity

                                                              Total                                      Men                                       Women                                                         
  ----------------------------------------------------------- ------------------------------------------ ----------------------------------------- ----------------------------------------- ------------ ------ ------------
  **Model 1**                                                 60/1203^[†](#t2f2){ref-type="table-fn"}^   34/573^[†](#t2f2){ref-type="table-fn"}^   26/630^[†](#t2f2){ref-type="table-fn"}^                       
  Sex, male                                                   1.69                                       0.97; 2.94                                                                                              
  Lipoprotein(a)^[¶](#t2f1){ref-type="table-fn"}^, 2.9-fold   1.22                                       1.03; 1:45                                1.53                                      1.19; 1:96   0.94   0.74; 1:20
  SHBG^[¶](#t2f1){ref-type="table-fn"}^, 1.7-fold             1.11                                       0.88; 1:39                                1.05                                      0.75; 1:48   1.17   0.86; 1:59
  C-react. protein^[¶](#t2f1){ref-type="table-fn"}^, 3-fold   1.06                                       0.87; 1:27                                1.05                                      0.81; 1:37   1.04   0.79; 1:36
  Age, 11 years                                               1.54                                       1.18; 2:02                                1.61                                      1.10; 2:33   1.49   1.01; 2:17
  Statin drug usage, y/n                                      1.20                                       0.55; 2.62                                1.27                                      0.45; 3.59   0.98   0.28; 3:38
  **Model 2**                                                 75/1539^[†](#t2f2){ref-type="table-fn"}^   42/747^[†](#t2f2){ref-type="table-fn"}^   33/792^[†](#t2f2){ref-type="table-fn"}^                       
  Sex, male                                                   1.39                                       0.87; 2.08                                                                                              
  Age, 11 years                                               1.61                                       1.58; 2:02                                1.71                                      1.26; 2:31   1.49   1.07; 2:08
  Prediabetes (n=144)                                         0.98[\*](#t2f3){ref-type="table-fn"}       0.43; 2.25                                1.06                                      0.35; 3.23   0.88   0.26; 3.05
  Diabetes (n=294)                                            1.63[\*](#t2f3){ref-type="table-fn"}       0.96; 2.77                                1.74                                      0.86; 3.53   1.49   0.67; 3.36

log-transformed values;

number RF pos/number at risk.

Referent normoglycemic group (n=1113); SHBG - sex hormone-binding globulin

The association of RF positivity with diabetes and hypertension is seen in the logistic regression analyses in [Table 3](#T3){ref-type="table"}, along with age and selected markers (waist circumference and CRP) of low-grade inflammation. Diabetes was significantly associated with RF positivity (OR 1.98 in the whole sample, 95% CI 1.11; 3.52) and additively to age and waist circumference. RF positivity was not associated with hypertension in men and only tended to exhibit a non-significant 1.9-fold OR in women, independent of age, waist girth, and CRP.

###### 

Cross-sectional associations of rheumatoid factor positivity for type 2 diabetes and hypertension, adjusted for sex, age, waist circumference, and C-reactive protein

                                                              Total                                       Men                                        Women                                                          
  ----------------------------------------------------------- ------------------------------------------- ------------------------------------------ ------------------------------------------ ------------ ------ ------------
  **Diabetes**                                                244/1303^[†](#t3f2){ref-type="table-fn"}^   124/628^[†](#t3f2){ref-type="table-fn"}^   127/675^[†](#t3f2){ref-type="table-fn"}^                       
  Age, 11 years                                               1.27                                        1.09; 1.49                                 1.23                                       1.00; 1.49   1.28   1.06; 1.55
  RF positivity                                               1.98                                        1.11; 3.52                                 2.29                                       1.07; 4.88   1.60   0.64; 4.01
  Waist circumfer., 12 cm                                     1.80                                        1.53; 2.10                                 2.15                                       1.68; 2.74   1.56   1.27; 1.93
  C-reactive protein, 3-fold                                  1.01                                        0.91; 1.11                                 0.92                                       0.78; 1.06   1.10   0.95; 1.27
  Lipoprotein(a)^[¶](#t3f1){ref-type="table-fn"}^, 2.9-fold   0.99                                        0.91; 1.08                                 1.05                                       0.92; 1.19   0.95   0.84; 1.06
  **Hypertension**                                            785/1537^[†](#t3f2){ref-type="table-fn"}^   317/748^[†](#t3f2){ref-type="table-fn"}^   458/789^[†](#t3f2){ref-type="table-fn"}^                       
  Age, 11 years                                               2.19                                        1.92; 2.49                                 2.08                                       1.75; 2.47   2.31   1.92; 2.78
  RF positivity                                               1.43                                        0.83; 2.46                                 1.21                                       0.60; 2.43   1.91   0.78; 4.68
  Waist circumfer., 12 cm                                     1.70                                        1.49; 1.88                                 1.86                                       1.55; 2.23   1.58   1.34; 1.86
  C-reactive protein, 3-fold                                  1.12                                        1.04; 1.22                                 1.08                                       0.96; 1.21   1.17   1.04; 1.30

log-transformed values. Referent RF - negative.

number of cases/number at risk. Lp(a) was not measured in 16% of sample. Sex was not significant with respect to diabetes; female sex had a significant OR of 1.92 to hypertension

Discussion {#sec1-4}
==========

The autoantibody RF, commonly observed in patients with RA, was found in 5% in this sample of a middle-aged and elderly general population. RF positivity was significantly and independently associated with Lp(a), particularly in men. Positive RF titers were inversely associated with SHBG, though SHBG tended to have a positive independent association with RF positivity. RF positivity was further associated with prevalent type 2 diabetes and additively to age, waist circumference, and serum CRP. These findings shed light on the immunological role of Lp(a), mediated by RF positivity, in the development of diabetes. RF positivity can be considered to reflect autoimmune activation underlying diseases, ranging from well-known RA to diabetes.

Clinical significance of RF {#sec2-5}
---------------------------

Detection of autoantibodies, such as RF and anti-cyclic citrullinated peptides, are valuable for early identification of patients with undifferentiated inflammatory arthritis at risk of developing RA ([@ref17]). Baseline RF positivity in patients with varying degrees of early inflammatory arthritis varied between 8% and 55% in 10 studies reviewed by Barra et al. ([@ref18]), and seroconversion rates in these patients were as low as 2%-5% at follow-up.

We could find no reports on the association of RF with diabetes. Prevalence rates of diabetes in patients with and without RA were similar in the report by Gabriel et al. ([@ref19]), in the NHANES III participants ([@ref20]), and in the female cohort of the Nurses' Health Study ([@ref21]). In contrast, in a large patient-centric health plan database, the prevalence of type 2 diabetes was significantly though moderately higher in RA patients than in matched controls ([@ref22]). These observations leave room for the possibility that RF-positive RA patients may have a higher likelihood of diabetes.

Association of Lp(a) with RF is remarkable {#sec2-6}
------------------------------------------

It is noteworthy that Lp(a), known to be in weak correlation with other lipid and non-lipid parameters ([@ref5], [@ref8], [@ref9]), emerged as the most significant covariate of RF positivity in our analysis, which was, in turn, associated with diabetes. This finding is consistent with a report on circulating Lp(a) being linked to diabetes ([@ref23]). In the large prospective Women's Health Study ([@ref23]), Lp(a) was found to be inversely associated with the development of type 2 diabetes, with a roughly 25% higher relative risk in the bottom quintile compared with the remainder of the sample. This observation, unexpected to the authors, can be explained by a mechanism of immune complex formation involving Lp(a) and interfered assay results due to failure by capturing antibodies. The TARF study has generated numerous articles on instances of Lp(a) assayed as "reduced" and the clearly increased risk of diabetes ([@ref24]), the enhanced proinflammatory state with HDL dysfunction ([@ref25]), autoimmune activation involving serum creatinine ([@ref26]), asymmetric dimethylarginine ([@ref27]) or other serum proteins, and the autoimmune physiopathology shared between diabetes and CHD ([@ref28]).

Correlation between SHBG and Lp(a) disparate by RF status {#sec2-7}
---------------------------------------------------------

A major and novel finding was that Lp(a) declined significantly with decreasing SHBG among RF-negative individuals, whereas Lp(a) rose significantly with both declining SHBG and rising RF titers among seropositive subjects, regardless of sex, except that the titer was less weakly correlated with Lp(a) in women. Together with the finding that SHBG tended to be higher in seropositive than in -negative subjects, these findings can be explained only by incriminating immune complex formation between Lp(a), damaged in oxidative stress, and SHBG (and/or an HDL-related protective protein) in RF positivity. At a threshold of above-average SHBG concentration, the concurrence of impaired function of HDL and excess Lp(a), both induced by a heightened pro-inflammatory state mediated by decreasing SHBG, may provide the setting for RF positivity and increasing titers. In other words, the epitope of oxidized Lp(a), interfered with by the interacting capture antibody/SHBG and no longer immunoassayable, will result in apparently "reduced" Lp(a) levels in the presence of elevated or normal SHBG. The side finding of both HDL-cholesterol and apoA-I being higher in seropositive than in RF-negative women is consistent with HDL dysfunction, shown in the TARF nondiabetic cohort ([@ref29]). Serum SHBG is well recognized to be a determinant of MetS ([@ref30]) or diabetes ([@ref31]).

Elevated serum concentrations of β2-glycoprotein I-Lp(a) complexes have been shown in case-control studies by two different research groups to be associated with the presence of coronary artery disease ([@ref32]), systemic lupus erythematosus ([@ref33]), and rheumatoid arthritis ([@ref34]). Immunoassay results may be interfered with due to failure by capture antibodies to recognize oxidized epitopes interacting with β2-GPI, ubiquitously present in plasma ([@ref32]).

Relation to inflammatory and metabolic disorders {#sec2-8}
------------------------------------------------

Periodontal disease, proposed as having an etiologic or modulating role in cardiovascular disease and diabetes, is associated with RA, on which seropositivity toward RF impacts ([@ref35]). Evidence exists that autoantibodies, such as RF, can develop several years before the onset of clinical disease ([@ref36], [@ref37]), which suggests that environmental factors may influence disease susceptibility during early life.

Immunologic role of Lp(a) and gender modulation {#sec2-9}
-----------------------------------------------

In vitro, Lp(a) binds to extracellular matrix proteins, such as fibrin and defensins, peptides that are released by neutrophils during inflammation ([@ref38]). Lp(a) may operate in two ways: a) excess plasma levels may provide a proinflammatory milieu, which in turn may induce immune activation that leads to RF positivity, concomitantly inducing inflammatory and cardiometabolic diseases (this pathway is typical in men of most ethnicities), and b) Lp(a) may initiate by antigenicity of its apo(a) moiety immune responses, with concomitant involvement of Lp(a) protein, in which case an inverse relationship between Lp(a) protein and the immune process (RF positivity) or outcome disorder may be inverse (this pathway is typical in women). Given the independent positive association of Lp(a) with RF positivity and the underestimation in this state of circulating Lp(a), the Lp(a) concentrations in seropositive subjects are likely substantially higher than our (or others') data reflect.

Overall, among male and female diabetics of a large metaanalysis ([@ref5]), diabetes was associated with significantly lower Lp(a) than in non-diabetic participants, suggesting that this lipo-protein may be involved in immune responses in the majority of diabetic people. In the association with diabetes, the partial gender-specific mediation of RF positivity may be due to the herein documented weaker correlation between Lp(a) and RF titers in women than in men.

Hypothesis and implications {#sec2-10}
---------------------------

This study supports our previously proposed hypothesis ([@ref7]) that inflammation is mediated-beyond central obesity-by reduced mass or activity of the PAF-AH enzyme, secreted in human macrophages ([@ref39]) and found to be more concentrated on Lp(a). The low-grade inflammation induces inadequate hydrolysis of excess oxidized phospholipids in Lp(a) and alterations in the composition of HDL particles, all potentially promoting autoimmune activation ([Fig. 2](#F2){ref-type="fig"}). One of the possible consequences is RF positivity; other consequences being inflammatory rheumatic diseases ([@ref12]); periodontal disease, metabolic disorders, such as hypertension or diabetes; or cardiovascular disease. Recognition of RF positivity as a marker of autoimmune activation associated with enhanced low-grade inflammation may be useful in the early detection of a variety of chronic diseases. Much further research is obviously needed in this area.

![Schema depicts hypothesized role of lipoprotein (Lp)(a), autoimmune activation, and rheumatoid factor positivity (RF) in the development of type 2 diabetes and hypertension (metabolic disorders). Mediated by low platelet activating factor (PAF-AH) levels, derived from macrophages and Lp(a), excess Lp(a) and/or oxidized phospholipids lead to an outcome either simply as shown (usually observed in men) or by involvement of Lp(a) itself in the immune process, yielding reduced Lp(a) lipoprotein due to partial non-assayability (typically observed in women). HDL composition and apoA-I, as well as other presumably damaged serum peptides/proteins, such as creatinine, thyrotropin, acylation-stimulating protein, or asymmetric dimethylarginine, may compose the autoimmune complex](AJC-15-782-g002){#F2}

Study limitations {#sec1-5}
=================

The cross-sectional design of the study limits the inference of a causal relationship of the elicited RF positivity. The study sample, exhibiting a relatively high prevalence of diabetes, both forms a strength and may limit the applicability of the findings to some other ethnic populations at large. The availability of measurements of relevant variables that are uncommonly studied in subjects with RF positivity forms a further strength of the study.

Conclusion {#sec1-6}
==========

In a general population, RF positivity is directly and independently associated with circulating Lp(a) and prevalent type 2 diabetes, additively to age, waist circumference, and serum CRP RF positivity that marks the likelihood of diabetes is also associated with elevated serum SHBG, suggesting involvement of both in the autoimmune complex, likely induced by apo(a) of Lp(a). In women, in whom Lp(a) is not independently associated with RF, a second type of Lp(a)-associated immune mechanism likely leads to "reduced" assayability of this lipoprotein. These novel pathophysiological pathways require much further research to illuminate the autoimmune activation underlying a variety of diseases of rheumatic, renal, or cardiometabolic origin.
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